Propanc Biopharma, Inc. — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Propanc appointed Carlo Campiciano as an independent board director effective July 8, 2026, replacing a resigned independent member. Compensation: $45,000 USD annually paid quarterly, plus equity issuance of 0.5–4.99% based on milestone achievements. Board now consists of five members: two executive, three independent. Standard director duties, confidentiality, and indemnification provisions apply.
Why this rating
Routine board replacement with modest fixed cost (~0.09% of $48K market cap); standard governance event for micro-cap company.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.